Suppr超能文献

通过体容积描记法测定支气管哮喘患者中糖皮质激素(布地奈德)与抗白三烯药物(孟鲁司特)疗效的比较。

Comparison of Glucocorticoid (Budesonide) and Antileukotriene (Montelukast) Effect in Patients with Bronchial Asthma Determined with Body Plethysmography.

作者信息

Lajqi Njomza, Ilazi Ali, Kastrati Bashkim, Islami Hilmi

机构信息

Trifarm, Laboratory of Pharmaceutical Company, Fushe Kosove, Kosova.

Kosovo Occupational Health Institute, Clinical Centre N.N., Gjakova, Kosova.

出版信息

Acta Inform Med. 2015 Dec;23(6):347-51. doi: 10.5455/aim.2015.23.347-351.

Abstract

OBJECTIVE

Effect of glucocorticoids-budesonide and antileukotriene-montelukast in patients with bronchial asthma and bronchial increased reactivity was studied in this work.

METHODS

Parameters of the lung function are determined with Body plethysmography. Raw and ITGV were registered and specific resistance (SRaw) was also calculated.

RESULTS

Results of this research, in patients with bronchial asthma, indicate that glucocorticoids - budesonide (Pulmicort; 2 × 2 mg inh) has significant action (p< 0.01) on reduction of the specific resistance (SRaw) of airways, applied to the same patients 3 days after administration of montelukast, at home (2 × 10 mg). Three days after administration of the montelukast, antileukotriene medicine, at home, on the fourth day same patients administered a capsule of montelukast, 10 mg dose per os, and significantly (p < 0.05) reduced the increased bronchomotor tonus; and the effect of the control with salbutamol (beta2-adrenergic agonist) is effective in removal of the increased bronchomotor tonus, causing significant decrease of the resistance (Raw), respectively of the specific resistance (SRaw), (p < 0, 01).

CONCLUSION

This suggests that the bronchodilator effect of glucocorticoids is more powerful than of the leukotriene, because glucocorticoids terminate the early stage of chemical mediator release (prostaglandins PgD2, SRS, and leukotriene LTC4, LTD4, LTE4 and Cytokinins also etc.) as powerful bronchoconstriction substances, whilst antileukotriene substances does not have this feature.

摘要

目的

本研究探讨糖皮质激素布地奈德和抗白三烯药孟鲁司特对支气管哮喘及支气管反应性增高患者的影响。

方法

采用体容积描记法测定肺功能参数。记录气道阻力(Raw)和比气道传导率(sGaw),并计算比气道阻力(SRaw)。

结果

本研究结果表明,对于支气管哮喘患者,糖皮质激素布地奈德(普米克;2×2mg吸入)对降低气道比气道阻力(SRaw)有显著作用(p<0.01),在患者在家服用孟鲁司特(2×10mg)3天后应用。在家服用孟鲁司特3天后,在第四天同一患者口服10mg剂量的孟鲁司特胶囊,可显著(p<0.05)降低支气管运动张力增高;而用沙丁胺醇(β2肾上腺素能激动剂)对照可有效消除支气管运动张力增高,使气道阻力(Raw)和比气道阻力(SRaw)分别显著降低(p<0.01)。

结论

这表明糖皮质激素的支气管舒张作用比白三烯更强,因为糖皮质激素可终止化学介质释放的早期阶段(前列腺素PgD2、慢反应物质以及白三烯LTC4、LTD4、LTE4和细胞因子等),这些都是强效支气管收缩物质,而抗白三烯药物没有这一特性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9530/4720827/dd3029b2828e/AIM-23-347-g002.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验